How effective is lurbinectedin for small cell lung cancer?
Lurbinectedin (brand name Zepzelca) is FDA-approved for metastatic small cell lung cancer (SCLC) in adults after platinum-based chemotherapy. In the phase 3 ATLANTIS trial, it combined with doxorubicin showed an overall response rate (ORR) of 22% versus 16% for topotecan (standard control), but median overall survival (OS) was 9.3 months versus 8.6 months—not statistically significant.[1] As monotherapy in the phase 2b basket trial (for relapsed SCLC), ORR reached 35.2%, with median duration of response at 5.3 months and median OS at 9.3 months.[2] Progression-free survival (PFS) was 3.5 months. Real-world data from 2023 studies report similar ORR around 30-40% in second-line use, with better tolerance than topotecan.[3]
What about effectiveness in other cancers like mesothelioma or ovarian?
Lurbinectedin targets transcription factors and DNA repair, showing activity beyond SCLC. In malignant pleural mesothelioma, phase 2 trials reported ORR of 23-33% as monotherapy post-platinum/pemetrexed, with median PFS 4-5 months and OS 9-11 months.[4] For platinum-resistant ovarian cancer, ORR is 25-30% in phase 2 data, often combined with other agents like doxorubicin.[5] Basket trials across 11 tumor types (e.g., endometrial, colorectal, thymic) yielded an overall ORR of 17.1%, highest in SCLC (35%) and mesothelioma (21%).[6] No approvals outside SCLC yet; ongoing trials test combinations in sarcomas and neuroendocrine tumors.
How does lurbinectedin compare to standard treatments?
Versus topotecan in relapsed SCLC, lurbinectedin has higher ORR (35% vs 15-25%) and better tolerability (less neutropenia, anemia), though OS benefits are modest.[2][7] It outperforms irinotecan in some head-to-head analyses for PFS. In mesothelioma, it matches pemetrexed-based regimens in response but with less toxicity. Limitations include short response duration (under 6 months typically) and no OS edge in large trials, positioning it as a second-line option rather than first-line curative therapy.
What do ongoing trials and biomarkers say about broader effectiveness?
Trials like LAGOON (phase 3, extensive-stage SCLC first-line with atezolizumab) report interim PFS hazard ratio 0.68 favoring lurbinectedin arm.[8] STELLAR-304 (SCLC post-immunotherapy) targets ORR improvement. Effectiveness ties to STK11 mutations or low RB1 loss; responders often have high tumor mutational burden. No DrugPatentWatch data on patents affecting efficacy trials.[9]
Sources
[1]: FDA Approval Summary
[2]: JAMA Oncology, 2020
[3]: Lung Cancer, 2023 real-world study
[4]: ESMO Open, 2022 mesothelioma trial
[5]: Gynecol Oncol, 2021 ovarian data
[6]: Lancet Oncol, 2021 basket trial
[7]: Ann Oncol topotecan comparison
[8]: ASCO 2024 LAGOON update
[9]: DrugPatentWatch.com - Lurbinectedin